WuXi STA Finalizes Acquisition of BMS’ Swiss Manufacturing Facility
WuXi STA has finalized its acquisition of Bristol Myers Squibb’s drug product manufacturing facility based in Couvet, Switzerland.
According to a Aug. 3, 2021 press release, WuXi STA—a subsidiary of WuXi AppTec—has finalized its acquisition of Bristol Myers Squibb’s (BMS’) drug product manufacturing facility based in Couvet, Switzerland.
Plans for the acquisition were announced earlier in 2021, and with the successful completion, the newly acquired site is the first in Europe for WuXi STA. The Swiss facility expands WuXi STA’s capacity on a global scale and will afford the company greater access to the European market.
“We are delighted to have added the Couvet site to our global supply network and are excited to welcome its highly skilled team to the WuXi STA family,” said Minzhang Chen, Co-CEO of WuXi AppTec, in the press release. “Through combining resources of the Couvet site with our other facilities, we continue strengthening and broadening our capacity and capabilities to better support our global customers in delivering innovative medicines to patients in need.”
Source: WuXi STA
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
